

Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2

Martin Šmíd^{a,b,1}, Luděk Berec^{a,c,d}, Ondřej Májek^{e,f}, Tomáš Pavlík^{e,f}, Jiří Jarkovský^{e,f}, Jakub Weiner^{a,g}, Lenka Příbylová^h, Tamara Barusová^{i,j}, and Jan Trnka^{a,k}

^aCentre for Modelling of Biological and Social Processes, Na břehu 497/15, 19000 Praha 9, Czech Republic; ^bCzech Academy of Sciences, Institute of Information Theory and Automation, Pod Vodárenskou věží 4, 18200 Praha 8, Czech Republic; ^cCzech Academy of Sciences, Biology Centre, Institute of Entomology, Department of Ecology, Branišovská 31, 37005 České Budějovice, Czech Republic; ^dCentre for Mathematical Biology, Institute of Mathematics, Faculty of Science, University of South Bohemia, Branišovská 1760, 37005 České Budějovice, Czech Republic; ^eInstitute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 126/3, 62500 Brno, Czech Republic; ^fInstitute of Health Information and Statistics of the Czech Republic, Palackého náměstí 4, 12801 Praha 2, Czech Republic; ^gSiesta Labs, Konopišťská 739/16, 10000 Praha 10, Czech Republic; ^hDepartment of Mathematics and Statistics, Faculty of Science, Masaryk University, 61137 Kotlářská 2, Brno, Czech Republic; ⁱFirst Faculty of Medicine, Charles University, Kateřinská 32, 12108 Praha 2, Czech Republic; ^jCzech Academy of Sciences, Institute of Computer Science, Department of Statistical Modelling, Pod Vodárenskou věží 2, 18207 Praha 8, Czech Republic; ^kDepartment of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Ruská 87, 10000 Praha 10, Czech Republic

This manuscript was compiled on February 23, 2022

The Omicron variant of the SARS-CoV-2 virus carries mutations, which enable it to evade immunity conferred by vaccines and previous infections. We used a Cox proportional hazards model and a logistic regression model on individual-level data on all laboratory-confirmed SARS-CoV-2 infections in the Czech Republic to estimate the relative risk of infection, hospitalization, including severe states, for Delta and Omicron variants, adjusting for sex, age, previous infection, vaccine type and vaccination status. A recent (<2 months) two-dose vaccination reached VE 43% (95% CI: 42-44) against infection by Omicron compared to 73% (95% CI: 72-74) against Delta. A recent booster increased VE to 56% (95% CI: 55-56) against Omicron infection compared to 90% (95% CI: 90-91) for Delta. The VE against Omicron hospitalization of a recent two-dose vaccination was 45% (95% CI: 29-57), with a recent booster 87% (95% CI: 84-88). The VE against the need for oxygen therapy due to Omicron was 57% (95% CI: 32-72) for recent vaccination, 90% (95% CI: 87-92) for a recent booster. Post-infection protection against Omicron hospitalization declined from 68% (95% CI: 68-69) at <6 months to 13% (95% CI: 11-14) at >6 months after a previous infection. A recent combination of a previous infection and vaccination was more protective than either alone with a slight benefit from a vaccination preceding an infection. Once infected, the OR for Omicron relative to Delta was 0.36 (95% CI: 0.34-0.38) for hospitalization, 0.24 (95% CI: 0.22-0.26) for oxygen therapy, and 0.24 (95% CI: 0.21-0.28) for ICU admission.

covid-19 | post-infection immunity | vaccine effectiveness | SARS-CoV-2 | Omicron variant | hospitalization

The B.1.1.529 (Omicron) variant of SARS-CoV-2 was first detected in South Africa in November 2021, immediately designated a variant of concern by the WHO (1) and thereafter seen quickly to spread throughout most of the world. This rapid spread was at least in part brought about by a degree of immune evasion due to a large number of mutations in the viral S-protein, which led to changes in epitopes recognised by antibodies elicited by vaccination or previous infection (2). Together with non-pharmacological interventions such as face masks, distancing, ventilation of interior spaces testing and isolating, vaccination is among the most effective means of individual and collective protection from the impacts of the pandemic. The immune evasion by the Omicron variant thus caused concern and led to a lot of interest in both laboratory and real-life epidemiological data that could accurately measure this phenomenon.

Since December 27, 2020 the inhabitants of the Czech

Republic have been receiving covid-19 vaccines with the largest number vaccinated with the mRNA vaccine Comirnaty (BNT162b2, Pfizer/BioNTech), followed by Spikevax (mRNA-1273, Moderna), and the adenovirus-based vector vaccines Vaxzevria (ChAdOx1 nCoV-19, AstraZeneca) and Janssen Covid-19 Vaccine (Ad26.CoV2.S, Johnson&Johnson, further abbreviated as Janssen) (3). By February 13, 2022, the end of our study period, 68% of the population had a complete vaccination and 39% received a booster dose (3)

The first case of the Omicron variant in the Czech Republic was detected at the end of November 2021, its proportion of recorded cases rapidly rose and by January 10, 2022 it became the dominant variant, see Figure 1. An increasing number of infections among fully vaccinated and re-infections indeed suggests that immune evasion poses a significant risk to further covid-19 development (3).

In this study, we estimate how the protection due to vaccination or previous SARS-CoV-2 infection against covid-19 infection, hospital admission, oxygen therapy and ICU admission varies in relation to the virus variant and time elapsed for the whole population of the Czech Republic.

Methods

Study population and data sources. The analyses are based on data from the Czech National Information System of Infec-

Significance Statement

A nation-wide study shows that the protection of a previous infection or vaccination is lower against Omicron compared to Delta variant of SARS-CoV-2 and further declines with time. A booster dose or a combination of post-infection immunity with a vaccine conferred significant benefit to individuals in the Omicron wave in the Czech Republic, which further strengthens the importance of vaccination as an effective public health measure.

LB, MŠ, JT and LP conceived this study. JJ, OM, JW, and TB prepared and checked the data. TP provided the methodological expertise, JW and MŠ conducted the analyses. LB and JT wrote the first draft of the manuscript. All authors contributed to writing the manuscript and interpreting the results. All authors approved the final version and had final responsibility for the decision to submit for publication.

All authors declare no competing interests.

¹To whom correspondence should be addressed. E-mail: smid@utia.cas.cz




Fig. 1. Number of recorded cases with assigned Delta (red) and Omicron (blue) variant and the proportion of PCR positive tests (black) tested for viral variants using multiplex PCR.

tious Diseases (ISID), which includes records of all individuals tested positive for SARS-CoV-2 in the Czech Republic since the beginning of covid-19 pandemic, including children (4). This database is overseen by the Czech Ministry of Health and operated by the Institute of Health Information and Statistics of the Czech Republic. Data are routinely collected in compliance with Czech legal regulations (Act on the Protection of Public Health). The Director of the Institute of Health Information and Statistics of the Czech Republic has granted an ethical approval of the retrospective analyses presented in this paper.

The ISID database collects demographic data (age, sex and region of residence), dates of vaccination, including the vaccine types for each dose, and dates of infection and potential reinfection, hospitalization including treatment type and the date of potential death with covid-19. Approximately half of data recorded in the study period include information on whether the infection is caused by the Omicron, Delta, some other variant, or that a variant discrimination was not performed. The information on the Omicron variant is based on results of multiplex PCR or viral genome sequencing, which are available only for a subset of all PCR-positive cases. The identification of Delta, Omicron, or other variant was computed using definition of viral S-protein mutations according to ECDC (5); the algorithm was tailored to multiplex PCR kits used in the Czech Republic in collaboration with the National Institute of Public Health and the National Reference Laboratory (6). Additional information on deaths from any cause come from the Death Certificate System; these data are used for censoring purposes only.

Study endpoints. We studied four types of events: (i) SARS-CoV-2 infection defined as a PCR-confirmed positive test of any type of sample regardless of the presence of symptoms, (ii) hospital admission of a person, who tested positive on a PCR test, within two weeks after the confirmed infection or earlier, (iii) use of any type of oxygen therapy (nasal oxygen, noninvasive ventilation, invasive mechanical ventilation, high-flow nasal oxygen, and extracorporeal membrane oxygenation) and (iv) admission to ICU during the hospitalization. All events were related to the date of infection report.

We examined events during the two month period from December 7, 2021 to February 13, 2022 during which Delta and Omicron switched dominance in the Czech Republic (Fig. 1).

Statistical analysis. A Cox regression with time-varying covariates was applied to estimate hazard ratios (HRs) for the outcomes of interest separately for each viral variant. In these analyses the infections by the variant other than the examined one and the infections lacking variant assignment were censored at the time of infection. Analogously to (7) we used calendar time instead of time from event occurrence as the time scale. Thus the time course of individual cases was modelled by means of “switching” dummy variables, corresponding to the development of the immune status after vaccination or past infection in 61-day periods for vaccination and 121-day periods for the time from the last infection.

The protection provided by vaccine (vaccine effectiveness) or previous infection is calculated by comparing hazards of the vaccinated and/or immunized individuals to those of the “control group” – those who have not been vaccinated and infected so far and subtracted from 1 using the equation:

$$Protection (VE) = 1 - \frac{Hazard_{protected}}{Hazard_{unprotected}} \quad [1]$$


Further we examine the post-infection immunity by estimating hazard ratios of infection of previously unvaccinated individual in relation to time elapsed from the infection. By using calendar time we were able automatically to incorporate the changing conditions of the epidemic, including non-pharmacological measures, seasonal effects, and the virus variant, as all of these phenomena can be included in the underlying baseline hazard function.

To examine the probabilities of hospitalization, oxygen therapy and ICU admission for an infected individual we use the logistic regression with the event of interest as the outcome and with all infections with an assigned viral variant as the data. By means of the dummy corresponding to the virus variant we compare the probabilities of the outcome for both the variants. Post-infection and post-vaccination status, age and sex are used as control variables. To estimate the amount of protection provided by the vaccination and/or past infection we run the logistic regression separately for infections by the two variants.

All calculations were performed using the R software (package *survival*). The algorithm used to transform data from the database into the package command inputs was coded in C++. See Supplementary material 1 for details.

127 **Results**

128 **Protection against infection.** First we looked at the protection
 129 conferred by vaccination or a previous infection against a new
 130 infection, since the protection against infection represents the
 131 potential to protect others at risk in the population. For
 132 vaccination and the Omicron variant the protection reached
 133 43% (95% CI 42-44) shortly after completing the full vacci-
 134 nation scheme, falling to 9% (95% CI 8-10) after more than
 135 two months. This protection increased to 56% (95% CI 55-56)
 136 shortly after receiving a booster dose, followed by a decline
 137 to 21% (95% CI 19-23) after more than two months. These
 138 numbers strongly contrast with the protection against the
 139 Delta variant, which was consistently higher at 73% (95% CI
 140 72-74), 57% (95% CI 56-58), 90% (95% CI 90-91) and 82%
 141 (95% CI 79-84), respectively. Similar degrees of protection
 142 against infection are conferred also by the post-infection immu-
 143 nity: 68% (95% CI 68-69) shortly after infection (2-6 months,
 144 a positive test during the first two months after an infection
 145 is not considered a reinfection by definition) and 13% (95%
 146 CI 11-14) after six months for Omicron, versus 95% (95% CI
 147 94-96) shortly after infection and 83% (95% CI 82-84) after
 148 six months for Delta (Figure 2). Based on the past preva-
 149 lence of viral variants it can be expected that the infections
 150 older than 6 months were mostly due to the original Wuhan,
 151 D614G and Alpha variants, while the more recent ones were
 152 predominantly due to Delta. As we show in the Supplemen-
 153 tary material 2, Sections 11 and 12, explicit accounting for the
 154 vaccine type Comirnaty (BNT162b2, Pfizer/BioNTech) and
 155 Spikevax (mRNA-201273, Moderna) gave values of effective-
 156 ness comparable with the analyses of pooled data reported
 157 here in the main text.



158 **Fig. 2.** Protection provided by vaccination or previous infection against infection by
 159 the Omicron and Delta variants of the SARS-CoV-2 virus. Inf6-, previous infection <6
 160 months ago; Inf6+, previous infection >6 months ago; Full2-, complete vaccination <2
 161 months ago; Full2+, complete vaccination >2 months ago; Booster2-, booster dose
 162 <2 months ago; Booster2+, booster dose >2 months ago. Shown are point estimates
 163 of protection with 95% CI.

158 We had enough data to examine all the combinations in
 159 which a previous infection preceded vaccination. As expected,
 160 protection declined with time elapsed from the previous infec-
 161 tion or vaccination (Tables 1 and 2). For the Delta variant, any
 162 combination provided $\geq 95\%$ protection against infection (Ta-
 163 ble 2). This protection remained quite high also for Omicron
 164 when the previous infection was recent, falling to lower values

165 for an older previous infection, but even then the protection
 166 was significantly higher than for a vaccination or previous
 167 infection alone (Table 1). We also analysed cases, where a
 168 vaccination preceded a previous infection, and conclude that
 169 when the protection is high (against Delta) then the order
 170 of events does not matter (see description of Tab. 2). How-
 171 ever, when protection is lower (against Omicron), the situation
 172 when a previous infection followed a vaccination appeared to
 173 provide a higher protection than the inverse sequence (see the
 174 caption of Tab. 1). The protection provided by Full 2+ / Inf 6-
 175 combination was 89% (88-91) as compared to 86% (95% CI
 176 85-88) for Inf 6- / Full 2+.

Table 1. Protection due to various combinations of past infection preceding vaccination against infection for the Omicron variant of the SARS-CoV-2 virus. Infection in recent 6 months is denoted as Inf 6- and older Inf 6+, completed vaccination scheme is denoted Full 2- for completion in recent 2 months and Full 2+ for older completion, analogously for booster. In parentheses, 95% confidence intervals (CI) are given. The inverse immunisation order had a higher effect: more than 2 months old full vaccination followed by infection in recent 6 months had 89% (88-91%) for full vaccination.

δinf	Booster 2-	Full 2-	Booster 2+	Full 2+
Inf 6-	92% (89-94%)	82% (75-87%)	82% (72-89%)	86% (85-88%)
Inf 6+	74% (73-75%)	77% (76-78%)	48% (45-52%)	45% (44-46%)

Table 2. Protection due to various combinations of past infection preceding vaccination against infection for the Delta variant of the SARS-CoV-2 virus, 95% confidence intervals (CI) in parentheses. The inverse immunisation order: more than 2 months old full vaccination followed by infection in recent 6 months had protection 96% (90-98%) for full vaccination.

δinf	Booster 2-	Full 2-	Booster 2+	Full 2+
Inf 6-	95% (66-99%)	100% no case	100% no case	97% (94-98%)
Inf 6+	98% (98-99%)	98% (97-98%)	94% (89-97%)	96% (95-96%)

177 These levels of protection against infection provided by
 178 vaccination or previous infection were estimated from the
 179 complete set of data. A finer grained analysis of temporal
 180 dynamics of immunity waning after a previous infection was
 181 then conducted specifically for individuals that were previ-
 182 ously infected but remained non-vaccinated. For Omicron,
 183 the protection was estimated as 69% (95% CI 68-69) for 2-6
 184 months after previous infection, 48% (95% CI 46-50) for 7-10
 185 months, 34% (95% CI 33-35) for 11-14 months, and 17% (95%
 186 CI 15-18) for 14 and more months after previous infection.
 187 For Delta, on the contrary, these numbers were 93% (95% CI
 188 91-94), 91% (95% CI 90-92), 86% (95% CI 85-86), and 79%
 189 (95% CI 77-81), respectively.

190 **Protection against hospitalization.** Qualitatively similar pat-
 191 tern yet quantitatively consistently higher protection is seen
 192 against hospitalization (Tables 3), a need for oxygen therapy
 193 (Tables 6), and a need for intensive care (Tables 7). For ex-
 194 ample, a recent booster dose provides 87% protection against
 195 hospitalization, 90% against a need of oxygen therapy, and
 196 84% against a need of intensive care for the Omicron variant.
 197 Moreover, all combinations of previous infection and vaccina-

198 tion present in our data appear to provide nearly complete
 199 protection against Omicron as regards hospitalization (Tables
 200 4 and 5) as well as against need of oxygen therapy or intensive
 201 care (no cases have been observed for such situations).

Table 3. Vaccine effectiveness and protection provided by post-infection immunity against hospitalization, for the Omicron and Delta variants of the SARS-CoV-2 virus, 95% confidence intervals (CI) in parentheses.

Effect ag. Hosp.	Omicron	Delta
Full 2-	45% (29-57%)	75% (68-80%)
Full 2+	29% (21-37%)	79% (78-81%)
Booster 2-	87% (84-88%)	98% (97-98%)
Booster 2+	79% (75-83%)	97% (95-98%)
Inf 6-	87% (73-94%)	100% (no case)
Inf 6+	92% (86-96%)	95% (93-96%)

Table 4. Protection due to various combinations of past infection preceding vaccination against hospitalization for the Omicron variant of the SARS-CoV-2 virus, 95% confidence intervals (CI) in parentheses. The inverse immunisation order: more than 2 months old full vaccination followed by infection in recent 6 months had protection 94% (78-99%)

ρ Hosp	Booster 2-	Full 2-	Booster 2+	Full 2+
Inf 6-	100% no case	100% no case	72% (0-96%)	93% (49-99%)
Inf 6+	98% (95-99%)	97% (80-100%)	97% (87-99%)	90% (84-94%)

Table 5. Protection due to various combinations of past infection preceding vaccination against hospitalization for the Delta variant of the SARS-CoV-2 virus, 95% confidence intervals (CI) in parentheses. The inverse immunisation order: more than 2 months old vaccination followed by infection in recent 6 months had protection 100% (no case) for full vaccination.

δ Hosp	Booster 2-	Full 2-	Booster 2+	Full 2+
Inf 6-	100% no case	100% no case	100% no case	100% no case
Inf 6+	100% (99-100%)	98% (95-99%)	98% (86-100%)	98% (98-99%)

Table 6. Vaccine effectiveness and protection provided by post-infection immunity against hospitalization with a need for oxygen therapy, for the Omicron and Delta variants of the SARS-CoV-2 virus, 95% confidence intervals (CI) in parentheses.

Effect ag. O_2	Omicron	Delta
Full 2-	57% (32-72%)	82% (76-87%)
Full 2+	32% (20-43%)	82% (80-83%)
Booster 2-	90% (87-92%)	98% (98-98%)
Booster 2+	85% (80-88%)	97% (95-98%)
Inf 6-	81% (40-94%)	100% (no case)
Inf 6+	88% (72-94%)	98% (95-99%)

202 **Risk of a severe outcome for Omicron vs. Delta.** Finally, our
 203 logistic regression analyses show that once infected, the odds
 204 ratio for hospitalization with Omicron relative to Delta is 0.36
 205 (0.34-0.38), for a need of oxygen therapy with Omicron relative
 206 to Delta is 0.24 (0.22-0.26), and for a need of intensive care with

Table 7. Vaccine effectiveness and protection provided by post-infection immunity against hospitalization with a need for intensive care, for the Omicron and Delta variants of the SARS-CoV-2 virus, 95% confidence intervals (CI) in parentheses.

Effect ag. ICU	Omicron	Delta
Full 2-	58% (3-82%)	84% (72-91%)
Full 2+	37% (12-55%)	86% (83-88%)
Booster 2-	83% (75-89%)	98% (97-99%)
Booster 2+	60% (37-74%)	97% (92-99%)
Inf 6-	83% (0-98%)	100% (no case)
Inf 6+	66% (15-86%)	97% (90-99%)

Omicron relative to Delta is also 0.24 (0.21-0.28). Moreover,
 once hospitalized, the odds ratio for a need of oxygen therapy
 with Omicron relative to Delta is 0.44 (0.39-0.49) and for a
 need of intensive care with Omicron relative to Delta is 0.64
 (0.52-0.72).

Discussion and Conclusions

Our data support the existing evidence that the Omicron
 variant of SARS-CoV-2 evades to a significant extent both the
 post-vaccination and post-infection immunity (2, 8-11). The
 VEs of all the vaccines used in the Czech Republic are lower
 for Omicron compared to Delta. As we previously observed
 with Alpha and Delta (12), the protection against infection by
 the Omicron variant wanes over time too. However, a booster
 vaccine dose provides robust and lasting or slowly waning
 protection against hospitalization, the need for oxygen therapy
 and intensive care. The combined post-infection and post-
 vaccination immunity is the most protective regardless of the
 exact sequence of events, suggesting that the best protective
 strategy before a coming wave is to vaccinate all individuals,
 whether previously vaccinated or with a previous covid-19
 infection.

We are aware of the complicated interpretation of the hos-
 pitalization data for the Omicron wave, as the very high basic
 reproduction number R_0 of this variant (13) translated into
 the very high prevalence of infection in the population at the
 peak of the epidemic wave and a much higher proportion of
 hospitalized patients with covid-19 as a concomitant finding
 rather than the reason for admission. We therefore analysed
 separately the need for oxygen therapy and ICU admission
 as a more relevant measure of severe outcomes due to the
 Omicron infection.

Compared to the Delta variant, the protection provided by
 the post-infection or post-vaccination immunity is lower for
 the Omicron variant but at the same time the Omicron variant
 appears less severe than the Delta variant and the odds ratio
 for oxygen therapy or ICU admission are both approximately
 about one quarter compared to the Delta variant.

A common limitation of studies like ours is the fact that
 only a certain portion of infections is reported (ascertainment
 rate). We believe this phenomenon does not affect signifi-
 cantly our estimates of vaccine effectiveness, assuming that
 the ascertainment rate is the same for the vaccinated and the
 unvaccinated alike and we have no evidence to the contrary.
 A difference in the ascertainment rate could also distort our
 estimates of the protection by the post-infection immunity;
 in particular, if there were undetected individuals with post-
 infection immunity in the control group, the infection risk of
 the population would be underestimated and, consequently,

255 the protection by infection underestimated as well. Our results
256 should be interpreted in terms of reported infections only.

257 **ACKNOWLEDGMENTS.** Data reported in this study and used for
258 the analyses are not public. De-identified individual-level data are
259 available to the scientific community. Requests should be submitted
260 to the Institute of Health Information and Statistics of the Czech
261 Republic (www.uzis.cz/index-en.php), together with a short de-
262 scription of their analysis proposals, where they will be assessed
263 based on relevance and scientific merit.

- 264 1. World Health Organization, Classification of Omicron (B.1.1.529): SARS-CoV-2 variant
265 of concern ([https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern)) (2021) Accessed: 2022-02-20.
- 266 2. M McCallum, et al., Structural basis of sars-cov-2 omicron immune evasion and receptor
267 engagement. *Science* **0**, eabn8652 (2022).
- 268 3. Ministry of Health of the Czech Republic, COVID-19: an overview of the actual situation in
269 the Czech Republic (in Czech) (onemocneni-aktualne.mzcr.cz/covid-19) (2020) Accessed:
270 2022-02-20.
- 271 4. M Komenda, et al., Complex reporting of the COVID-19 epidemic in the Czech Republic: Use
272 of an interactive web-based app in practice. *J Med Internet Res* **22**, e19367 (2020).
- 273 5. ECDC, SARS-CoV-2 variants of concern ([https://www.ecdc.europa.eu/en/covid-19/](https://www.ecdc.europa.eu/en/covid-19/variants-concern)
274 variants-concern) (2022) Accessed: 2022-02-20.
- 275 6. SZU, Charakterizace viru SARS-CoV-2 v České Republice dle diskriminačních PCR a
276 celogenomové sekvenace, 31. 1. 2022 ([http://www.szu.cz/uploads/Epidemiologie/Coronavirus/](http://www.szu.cz/uploads/Epidemiologie/Coronavirus/WGS_covid/2022_tydenni_hlaseni/SARS_CoV_2_podrobna_zprava_SZU_2022_01_31.pdf)
277 WGS_covid/2022_tydenni_hlaseni/SARS_CoV_2_podrobna_zprava_SZU_2022_01_31.
278 pdf) (2022) Accessed: 2022-02-20.
- 279 7. S Tartof, et al., Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large
280 integrated health system in the USA: a retrospective cohort study. *Lancet* **398**, 1407–1416
281 (2021).
- 282 8. W Dejnirattisai, et al., SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from
283 neutralizing antibody responses. *Cell* **185**, 467–484.e15 (2022).
- 284 9. M Hoffmann, et al., The omicron variant is highly resistant against antibody-mediated neutral-
285 ization: Implications for control of the COVID-19 pandemic. *Cell* **185**, 447–456.e11 (2022).
- 286 10. Z Cui, et al., Structural and functional characterizations of infectivity and immune evasion of
287 SARS-CoV-2 omicron. *Cell* (2022).
- 288 11. Y Cao, et al., Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
289 *Nature* (2021).
- 290 12. L Berec, et al., Real-life protection provided by vaccination, booster doses and previous
291 infection against covid-19 infection, hospitalisation or death over time in the czech republic: a
292 whole country retrospective view. *medRxiv* (2021).
- 293 13. H Nishiura, et al., Relative reproduction number of SARS-CoV-2 Omicron (B. 1.1. 529)
294 compared with Delta variant in South Africa (2022).
- 295

DRAFT

Supplementary material 1: Protection provided by covid-19 vaccines and previous infection against the Omicron variant

1 Dataset

2 In total, our dataset contains 8,282,080 records of vaccinated and/or SARS-CoV-2 positive persons, out of which 10,937 were
3 excluded for either inconsistency or the lack of valid sex and/or age information. Additional 97,855 records were excluded
4 as corresponding individuals died before 7. December 2021 which we set as the start date (34,145 were recorded to die from
5 covid-19, 63,740 from other reasons; see Table S3). As the source dataset consists only of those who were tested positive and/or
6 were vaccinated, we added subjects who were neither tested positive nor vaccinated. In particular, we completed each sex-age
7 category to the numbers reported by the Czech Statistical Office by December 31, 2020 – 10,701,777 inhabitants; consequently,
8 our sample truly reflected the sex and age structure of the whole population, containing all the positive and/or vaccinated
9 individuals. We neglected births and deaths of the added persons. Moreover, not all non-covid deaths were recorded as they
10 are reported with a delay.

11 Methods: a Cox regression with time-varying covariates

12 For the analyses of vaccine effectiveness and immunity protection, made separately for both the Omicron and Delta variant, we
13 use the Cox proportional hazards model with time-varying covariates.

14 The input of the model consists of one or more records for each subject. Each record corresponds to a time interval from time
15 T_1 to T_2 , in which the covariates are constant and in the interior of which none of the outcomes happened. Each record contains
16 indicators of outcomes `VariantInf`, `VariantHosp`, `VariantOxygen`, `VariantICU`, `DeadByCov`, `DeadByOther`, happening at
17 T_2 and the value of the covariates, valid in $[T_1, T_2)$. Undiscriminated infections and infections by other variants lead to
18 withdrawal from the study (right censoring). Deaths of covid (`DeadByCov`) or of other reasons (`DeadByOther`) lead to right
19 censoring at the time of the event as well. Fixed (non-time-dependent) covariates include sex (`Sex`) and age category (`AgeGr`).

20 Time is measured in days and we take the day before our study period (Dec 7th, 2021) as time zero. By default, for each
21 subject, the intervals cover the entire period from 7th. December 2021 to 13. February 2022. The period is shortened (censoring
22 takes place) if either:

- 23 • The subject is infected (except for the Infection analysis)
- 24 • The subject is infected by some other variant or the infection is not discriminated (in the Infection analysis)
- 25 • The subject is reported to die
- 26 • The subject is reported to obtain booster by Astra or Janssen
- 27 • The subject gets a vaccine (only in the reinfection analysis)

28 **Combined Immunity.** In these analyses, we let each individual to go through the several “immunity states” encoded into
29 `Immunity` covariate. The outcomes (events) are either (a confirmed) infection (`VariantInf`, may be repeated), hospitalization
30 (`VariantHosp`), oxygen therapy (`VariantOxygen`) or ICU admission (`VariantICU`).

31 The `Immunity` categorical covariate can take the following values:

32 `_noimmunity` meaning that the subject was neither vaccinated nor underwent (confirmed) infection,

33 `X_alone` meaning that the condition X happened,

34 `X_Y` which means that the condition X happened, being followed by condition Y in time.

35 The conditions X and Y could be:

36 `part` partially vaccinated (from 14 days of the dose application)

Table S1. Details on analyses by Cox regression.

Analysis	Outcome	Covariates
Infections	VariantInf	Immunity, Sex, AgeGr
Reinfections	VariantInf	InfPrior, Sex, AgeGr
Hospitalizations	VariantHosp	Immunity, Sex, AgeGr
Oxygen therapy	VariantOxygen	Immunity, Sex, AgeGr
ICU admission	VariantICU	Immunity, Sex, AgeGr
Detailed hospitalizations	VariantHosp	VaccStatus, InfPrior, Sex, AgeGr
Detailed oxygen therapy	VariantOxygen	VaccStatus, InfPrior, Sex, AgeGr
Detailed ICU admission	VariantICU	VaccStatus, InfPrior, Sex, AgeGr

37 **full12-** fully vaccinated no earlier than two months ago (from 14 days to $14 + 61 - 1 = 74$ days after the dose application)

38 **full12+** fully vaccinated earlier than two months ago (from 75 days from the application or earlier)

39 **boost2-** booster vaccinated no earlier than two months ago (from 14 days to 74 days after the dose application)

40 **boost2+** booster vaccinated earlier than tow months ago (from 75 days from the application or earlier)

41 **inf6-** underwent infection no earlier than six months (180 days) ago

42 **inf6+** underwent infection earlier than six months (180 days) ago.

43 **Re-infection Analysis.** When separately estimating the post-infection immunity we consider the infection by the examined
 44 variant (**VariantInf**) as the outcome. As the explanatory variable we take the categorical covariate **InfPrior** indicating the
 45 delay from the last infection, grouped by four months. The **InfPrior** covariate can take the following values:

46 **_noinf** no previous infection

47 **inf1** 60–180 days after the last confirmed infection (the re-infection cannot happen during the first 60 days by definition)

48 **inf2** 181–301 days after the last confirmed infection

49 **inf3** 302–422 days after the last confirmed infection

50 **inf4+** any later.

51 **Detailed Analyses.** Here, the outcomes include **VariantInf** (possibly repeated), **VariantHosp** or **VariantOxygen**. The time-
 52 varying covariates include **VaccStatus** and **InfPrior**. The **VaccStatus** is either **_novacc** (not vaccintaed) or takes the form
 53 **VSP** where

54 **V** denotes the vaccine (P-fizer, M-oderna, A-stra, J-anssen),

55 **S** denotes the state of vaccination (part - partial, full - full, boost - booster)

56 **P** denotes the time distance from the last vaccination

57 **S=part:** 1=first 61 days after the dose takes effect (14 days after application), 2=any later

58 **S=full:** 1=first 61 days after the dose takes effect (14 days after application), 2=next 61 days, 3=later

59 **S=boost:** 1=first 61 days after the dose takes effect (7 days after application), 2=later

60 The **InfPrior** covariate is as above.

61 Table [S1](#) summarizes all the analyses we made by means of Cox regression.

62 **Methods: a Logistic regression**

63 In theses analyses, the binary outcomes **Hosp**, **Oxygen**, **ICU** corresponding to the discriminated infections are explained by
 64 dummy **Variant** taking values either **Omicron** or **Delta**, the value of covariate **Immunity** valid at the time of the infection and
 65 constant covariates **AgeGr** and **Sex**. Table [S2](#) summarizes all these analyses.

66 **Software implementation**

67 The **coxph** function from **survival** R package was used for the Cox regression, the (**glm** function from **stats** R package) for the
 68 Logistic regression. The original software package was used to transform the source data to the input of the functions. The
 69 source code with example (unreal) data can be retrieved from <https://github.com/bisop-repo/omicronprotection>.

70 **Supplementary tables**

Table S2. Details on analyses by Logistic regression.

Analysis	Outcome	Covariates
Hospitalizations given infection	Hosp	Variant, Immunity, Sex, AgeGr
Oxygen given infection	Oxygen	Variant, Immunity, Sex, AgeGr
ICU given infection	ICU	Variant, Immunity, Sex, AgeGr
Oxygen given hospitalization	Oxygen	Variant, Immunity, Sex, AgeGr
ICU given hospitalization	ICU	Variant, Immunity, Sex, AgeGr

Table S3. Descriptive statistics: population and epidemic characteristics in the Czech Republic; ISID = the Czech National Information System of Infectious Diseases.

Age group	Number	Dataset		Population by 07/12/2021		Events from 07/12/2021				
		Data errors	Dead by covid-19	From ISID	Added	Total	Infect- ted	Hospit- talized	Dead covid-19	Dead other
0-11	434936	23	6	434890	932215	1367105	167628	798	1	3
12-15	357588	14	0	357563	98925	456488	109893	175	1	3
16-17	170567	5	2	170544	24472	195016	51543	112	0	1
18-24	577030	69	6	576961	92631	669492	118759	433	0	13
25-29	466101	50	21	465942	154983	620925	87595	479	1	15
30-34	552204	28	48	551972	166959	718931	106904	634	5	30
35-39	587595	52	76	587243	166067	753310	116199	724	13	39
40-44	713128	48	151	712476	180845	893321	130422	799	19	84
45-49	778086	44	298	776951	105635	882586	126795	971	38	105
50-54	603655	23	455	602068	89015	691083	81047	1029	67	167
55-59	581568	23	879	578874	90859	669733	63633	1321	141	251
60-64	527736	16	1668	523160	102305	625465	40469	1509	201	427
65-69	594362	21	3310	585657	86761	672418	29413	2374	370	727
70-74	572325	19	5541	557848	63329	621177	21452	2984	586	1160
75-79	418441	15	6670	401266	15935	417201	14150	3165	691	1231
80+	445102	9	15014	398765	48761	447526	14703	5983	1640	3304
Total	8380424	459	34145	8282080	2419697	10701777	1280605	23490	3774	7560
Errors	No age	9929	No sex			4815				

Table S4. Descriptive statistics: vaccine distribution among different age groups until November 20, 2021.


Age group	Completed vaccination				Booster doses				Total	
	Comirnaty	Spikevax	Vaxzevria	Janssen	Total	Comirnaty	Spikevax	Vaxzevria		Janssen
0-11	38353	55	3	11	38422	175	2	0	0	177
12-15	195722	4167	2	2	199893	16844	143	0	0	16987
16-17	120102	3052	33	341	123528	18058	689	0	0	18747
18-24	394263	26110	2348	44131	466852	105841	13953	2	12	119808
25-29	298948	25096	3547	36148	363739	93385	15294	4	10	108693
30-34	364532	28912	4877	37250	435571	131736	21530	3	10	153279
35-39	395946	31868	7156	37489	472459	165876	25716	10	27	191629
40-44	503173	40455	12059	41404	597091	249310	36474	17	33	285834
45-49	564756	44639	16643	43925	669963	321021	44898	17	40	365976
50-54	440085	37823	17806	34186	529900	274139	39573	19	41	313772
55-59	426529	37494	24522	31785	520330	293838	41891	21	40	335790
60-64	388409	36335	33399	28237	486380	307892	42194	23	47	350156
65-69	426983	45314	60188	27974	560459	381356	54634	39	97	436126
70-74	359947	58087	100680	20549	539263	379045	63896	59	128	443128
75-79	246125	46985	83302	12442	388854	276509	48422	53	106	325090
80+	264910	40559	67123	9655	382247	276295	42481	47	108	318931
Total	5428783	506951	433688	405529	6774951	3291320	491790	314	699	3784123

Protection provided by covid-19 vaccines and previous infection against the Omicron variant

Results of Statistical Estimation


February 23, 2022

1 Infections – Omicron




Immunity	entered	events
_noimmunity	799055	114191
boost2_alone	783053	31773
boost2+_alone	5313	8814
full2_alone	250234	11767
full2+_alone	4004420	91261
inf6_alone	25504	4882
inf6+_alone	542432	19148
part_alone	173116	2822
inf6-_boost2-	187	29
inf6-_boost2+	4	19
inf6-_full2-	737	36
inf6-_full2+	5669	420
inf6+_boost2-	87565	3927
inf6+_boost2+	517	927
inf6+_full2-	86763	1363
inf6+_full2+	825962	14516
full2+_inf6-	802	253
boost2+_inf6-	0	0
other	0	0
rare	0	0

2 Infections – Delta




Immunity	entered	events
_noimmunity	799055	53531
boost2-_alone	783053	2211
boost2+_alone	5313	272
full2-_alone	250234	1770
full2+_alone	4004420	28067
inf6-_alone	25504	62
inf6+_alone	542432	1627
part_alone	173116	1098
inf6-_boost2-	187	1
inf6-_boost2+	4	0
inf6-_full2-	737	0
inf6-_full2+	5669	10
inf6+_boost2-	87565	54
inf6+_boost2+	517	10
inf6+_full2-	86763	52
inf6+_full2+	825962	625
full2+_inf6-	802	6
boost2+_inf6-	0	0
other	0	0
rare	0	0

3 Re-infections – Omicron




Immunity	entered	events
_noimmunity	799055	114191
boost2-_alone	783053	31773
boost2+_alone	5313	8814
full2-_alone	250234	11767
full2+_alone	4004420	91261
inf6-_alone	25504	4882
inf6+_alone	542432	19148
part_alone	173116	2822
inf6-_boost2-	187	29
inf6-_boost2+	4	19
inf6-_full2-	737	36
inf6-_full2+	5669	420
inf6+_boost2-	87565	3927
inf6+_boost2+	517	927
inf6+_full2-	86763	1363
inf6+_full2+	825962	14516
full2+_inf6-	802	253
boost2+_inf6-	0	0
other	0	0
rare	0	0

4 Re-infections – Delta




Immunity	entered	events
_noimmunity	799055	53531
boost2-_alone	783053	2211
boost2+_alone	5313	272
full2-_alone	250234	1770
full2+_alone	4004420	28067
inf6-_alone	25504	62
inf6+_alone	542432	1627
part_alone	173116	1098
inf6-_boost2-	187	1
inf6-_boost2+	4	0
inf6-_full2-	737	0
inf6-_full2+	5669	10
inf6+_boost2-	87565	54
inf6+_boost2+	517	10
inf6+_full2-	86763	52
inf6+_full2+	825962	625
full2+_inf6-	802	6
boost2+_inf6-	0	0
other	0	0
rare	0	0

5 Hospitalizations – Omicron




Immunity	entered	events
_noimmunity	799369	833
boost2-_alone	783071	255
boost2+_alone	5313	175
full2-_alone	250248	68
full2+_alone	4004621	569
inf6-_alone	25504	7
inf6+_alone	542432	10
part_alone	173127	17
inf6-_boost2-	187	0
inf6-_boost2+	4	1
inf6-_full2-	737	0
inf6-_full2+	5556	1
inf6+_boost2-	87566	4
inf6+_boost2+	517	2
inf6+_full2-	86763	1
inf6+_full2+	825964	17
full2+_inf6-	915	2
boost2+_inf6-	0	0
other	0	0
rare	0	0

6 Hospitalizations – Delta




Immunity	entered	events
_noimmunity	799369	2806
boost2- _alone	783071	221
boost2+ _alone	5313	29
full2- _alone	250248	91
full2+ _alone	4004621	1280
inf6- _alone	25504	0
inf6+ _alone	542432	13
part_alone	173127	83
inf6- _boost2-	187	0
inf6- _boost2+	4	0
inf6- _full2-	737	0
inf6- _full2+	5556	0
inf6+ _boost2-	87566	1
inf6+ _boost2+	517	1
inf6+ _full2-	86763	1
inf6+ _full2+	825964	8
full2+ _inf6-	915	0
boost2+ _inf6-	0	0
other	0	0
rare	0	0

7 Oxygen therapy – Omicron




Immunity	entered	events
_noimmunity	799368	833
boost2- _alone	783071	255
boost2+ _alone	5313	175
full2- _alone	250248	68
full2+ _alone	4004620	569
inf6- _alone	25507	15
inf6+ _alone	542247	45
part _alone	173127	17
inf6- _boost2-	0	0
inf6- _boost2+	0	0
inf6- _full2-	0	0
inf6- _full2+	0	0
inf6+ _boost2-	0	0
inf6+ _boost2+	0	0
inf6+ _full2-	0	0
inf6+ _full2+	0	0
full2+ _inf6-	0	0
boost2+ _inf6-	0	0
other	0	0
interactions	1060778	71
rare	0	0

8 Oxygen therapy – Delta




Immunity	entered	events
_noimmunity	799368	2805
boost2- _alone	783071	221
boost2+ _alone	5313	29
full2- _alone	250248	91
full2+ _alone	4004620	1280
inf6- _alone	25507	0
inf6+ _alone	542247	26
part _alone	173127	83
inf6- _boost2-	0	0
inf6- _boost2+	0	0
inf6- _full2-	0	0
inf6- _full2+	0	0
inf6+ _boost2-	0	0
inf6+ _boost2+	0	0
inf6+ _full2-	0	0
inf6+ _full2+	0	0
full2+ _inf6-	0	0
boost2+ _inf6-	0	0
other	0	0
interactions	1060778	25
rare	0	0

9 ICU therapy – Omicron




Immunity	entered	events
_noimmunity	799368	833
boost2-_alone	783071	255
boost2+_alone	5313	175
full2-_alone	250248	68
full2+_alone	4004620	569
inf6-_alone	25507	15
inf6+_alone	542247	45
part_alone	173127	17
inf6-_boost2-	0	0
inf6-_boost2+	0	0
inf6-_full2-	0	0
inf6+_boost2-	0	0
inf6+_boost2+	0	0
inf6+_full2-	0	0
inf6+_full2+	0	0
full2+_inf6-	0	0
boost2+_inf6-	0	0
other	0	0
interactions	1060778	71
rare	0	0

10 ICU therapy – Delta




Immunity	entered	events
_noimmunity	799368	2805
boost2-_alone	783071	221
boost2+_alone	5313	29
full2-_alone	250248	91
full2+_alone	4004620	1280
inf6-_alone	25507	0
inf6+_alone	542247	26
part_alone	173127	83
inf6-_boost2-	0	0
inf6-_boost2+	0	0
inf6-_full2-	0	0
inf6-_full2+	0	0
inf6+_boost2-	0	0
inf6+_boost2+	0	0
inf6+_full2-	0	0
inf6+_full2+	0	0
full2+_inf6-	0	0
full2+_inf6+	0	0
boost2+_inf6-	0	0
boost2+_inf6+	0	0
interactions	1060778	25
rare	0	0

11 Infections by Vaccines - Omicron




Immunity	entered	events
_noimmunity	799055	114191
boost2-_alone	783128	31776
boost2+_alone	5316	8816
full2-_alone	252497	11825
full2+_alone	4006108	91329
inf6-_alone	25504	4882
inf6+_alone	542432	19148
part_alone	168995	2721
inf6-_boost2-	187	29
inf6-_boost2+	4	19
inf6-_full2-	927	40
inf6-_full2+	5684	420
inf6+_boost2-	87700	3934
inf6+_boost2+	519	928
inf6+_full2-	87376	1374
inf6+_full2+	829279	14550
full2+_inf6-	802	253
boost2+_inf6-	0	0
other	0	0
rare	14273	205

12 Infections by Vaccines - Delta




Immunity	entered	events
_noimmunity	799055	53531
boost2-_alone	783128	2212
boost2+_alone	5316	272
full2-_alone	252497	1776
full2+_alone	4006108	28077
inf6-_alone	25504	62
inf6+_alone	542432	1627
part_alone	168995	1068
inf6-_boost2-	187	1
inf6-_boost2+	4	0
inf6-_full2-	927	0
inf6-_full2+	5684	10
inf6+_boost2-	87700	54
inf6+_boost2+	519	10
inf6+_full2-	87376	52
inf6+_full2+	829279	627
full2+_inf6-	802	6
boost2+_inf6-	0	0
other	0	0
rare	14273	87

13 Hospitalizations by Vaccines - Omicron



Category	entered	events
Immunity	799369	833
_noimmunity	799369	833
boost2-_alone	783146	255
boost2+_alone	5316	175
full2-_alone	252511	71
full2+_alone	4006309	571
inf6-_alone	25504	7
inf6+_alone	542432	10
part_alone	169005	15
inf6-_boost2-	187	0
inf6-_boost2+	4	1
inf6-_full2-	927	0
inf6-_full2+	5571	1
inf6+_boost2-	87701	4
inf6+_boost2+	519	2
inf6+_full2-	87376	1
inf6+_full2+	829281	18
full2+_inf6-	915	2
boost2+_inf6-	0	0
other	0	0
rare	14275	3

14 Hospitalizations by Vaccines - Delta



Immunity	entered	events
_noimmunity	799369	2806
boost2-_alone	783146	221
boost2+_alone	5316	29
full2-_alone	252511	93
full2+_alone	4006309	1283
inf6-_alone	25504	0
inf6+_alone	542432	13
part_alone	169005	83
inf6-_boost2-	187	0
inf6-_boost2+	4	0
inf6-_full2-	927	0
inf6-_full2+	5571	0
inf6+_boost2-	87701	1
inf6+_boost2+	519	1
inf6+_full2-	87376	1
inf6+_full2+	829281	8
full2+_inf6-	915	0
boost2+_inf6-	0	0
other	0	0
rare	14275	3

15 Hospitalization given Infection

Variable		N	Odds ratio	p
Variant	Delta	89061	Reference	
	Omikron	223091	0.36 (0.34, 0.38)	<0.001
Immunity	_noimmunity	138077	Reference	
	boost2-_alone	22441	0.27 (0.24, 0.30)	<0.001
	boost2+_alone	5286	0.46 (0.40, 0.53)	<0.001
	full2-_alone	10628	0.83 (0.70, 0.98)	0.029
	full2+_alone	97378	0.43 (0.41, 0.46)	<0.001
	full2+_inf6-	317	0.27 (0.07, 0.76)	0.032
	inf6-_alone	3369	0.29 (0.13, 0.55)	<0.001
	inf6+_alone	15873	0.10 (0.06, 0.14)	<0.001
	inf6+_boost2-	2544	0.05 (0.02, 0.12)	<0.001
	inf6+_boost2+	540	0.11 (0.03, 0.28)	<0.001
	inf6+_full2-	1076	0.12 (0.02, 0.37)	0.003
	inf6+_full2+	11396	0.15 (0.10, 0.21)	<0.001
	part2-_alone	3227	1.14 (0.91, 1.42)	0.250
	AgeGr	_40-64	107414	Reference
0-24		108547	0.21 (0.19, 0.23)	<0.001
25-39		77090	0.39 (0.35, 0.43)	<0.001
65+		19101	18.76 (17.61, 20.00)	<0.001
Sex	M	150698	Reference	
	Z	161454	0.81 (0.77, 0.85)	<0.001

0.020.050.10.2 0.5 1 2 5 10

16 Oxygen given Infection

Variable		N	Odds ratio	p
Variants	Delta	89038	Reference	
	Omikron	223041	0.24 (0.22, 0.26)	<0.001
Immunity	_noimmunity	138077	Reference	
	boost2-_alone	22441	0.21 (0.19, 0.25)	<0.001
	boost2+_alone	5286	0.37 (0.29, 0.45)	<0.001
	full2-_alone	10628	0.54 (0.41, 0.70)	<0.001
	full2+_alone	97378	0.35 (0.32, 0.38)	<0.001
	full2+_inf6-	314	0.00 (0.00, 0.00)	1.0
	inf6-_alone	3361	0.00 (0.00, 0.00)	1.0
	inf6+_alone	15850	0.01 (0.00, 0.04)	<0.001
	inf6+_boost2-	2539	0.00 (0.00, 0.00)	1.0
	inf6+_boost2+	537	0.00 (0.00, 0.00)	1.0
	inf6+_full2-	1074	0.00 (0.00, 0.00)	1.0
	inf6+_full2+	11367	0.00 (0.00, 0.00)	0.9
	part2-_alone	3227	0.78 (0.57, 1.06)	0.1
	AgeGr	_40-64	107391	Reference
0-24		108545	0.04 (0.03, 0.06)	<0.001
25-39		77082	0.20 (0.17, 0.24)	<0.001
65+		19061	18.44 (17.01, 20.02)	<0.001
Sex	M	150658	Reference	
	Z	161421	0.72 (0.67, 0.77)	<0.001

1e-2861e-2291e-1721e-1151e-58 0.1

17 ICU given Infection

Variable		N	Odds ratio	p
Variant	Delta	89061	■ Reference	
	Omikron	223091	■ 0.24 (0.21, 0.28)	<0.001
Immunity	_noimmunity	138077	■ Reference	
	boost2-_alone	22441	■ 0.30 (0.23, 0.38)	<0.001
	boost2+_alone	5286	■ 0.65 (0.46, 0.90)	0.012
	full2-_alone	10628	■ 0.43 (0.25, 0.70)	0.001
	full2+_alone	97378	■ 0.33 (0.28, 0.38)	<0.001
	full2+_inf6-	317	┆■ 0.00 (0.00, 0.00)	0.979
	inf6-_alone	3369	■ 0.32 (0.02, 1.45)	0.262
	inf6+_alone	15873	■ 0.15 (0.05, 0.32)	<0.001
	inf6+_boost2-	2544	┆■ 0.00 (0.00, 0.00)	0.943
	inf6+_boost2+	540	┆■ 0.00 (0.00, 0.00)	0.973
	inf6+_full2-	1076	┆■ 0.00 (0.00, 0.00)	0.965
	inf6+_full2+	11396	■ 0.04 (0.00, 0.16)	<0.001
	part2-_alone	3227	■ 0.78 (0.44, 1.28)	0.359
	AgeGr	_40-64	107414	■ Reference
0-24		108547	■ 0.09 (0.06, 0.12)	<0.001
25-39		77090	■ 0.19 (0.14, 0.26)	<0.001
65+		19101	■ 10.24 (8.94, 11.76)	<0.001
Sex	M	150698	■ Reference	
	Z	161454	■ 0.55 (0.48, 0.62)	<0.001

1e-2211e-1771e-1331e-89 1e-45 0.1

18 Oxagen given Hospitalization

Variable		N	Odds ratio	p
Variant	Delta	4521	■	Reference
	Omikron	2235	■	0.44 (0.39, 0.50) <0.001
Immunity	_noimmunity	3788	■	Reference
	boost2-_alone	516	■	0.47 (0.38, 0.57) <0.001
	boost2+_alone	246	■	0.45 (0.34, 0.60) <0.001
	full2-_alone	175	■	0.39 (0.28, 0.55) <0.001
	full2+_alone	1920	■	0.56 (0.50, 0.63) <0.001
	inf6+_alone	1	■	147714.80 (0.00, NA) 0.952
	inf6+_full2+	1	■	0.00 (NA, 10308582286697.01) 0.959
	part2-_alone	109	■	0.54 (0.36, 0.82) 0.003
	AgeGr	_40-64	1568	■
0-24		445	■	0.12 (0.09, 0.16) <0.001
25-39		484	■	0.32 (0.25, 0.40) <0.001
65+		4259	■	1.64 (1.45, 1.86) <0.001
Sex	M	3330	■	Reference
	Z	3426	■	0.79 (0.71, 0.88) <0.001

1e-12 1e-07 0.01 1000 1e+08 1e+13

19 ICU given Hospitalization

Variable		N	Odds ratio	p	
Variant	Delta	4544	Reference		
	Omikron	2285	0.62 (0.53, 0.73)	<0.001	
Immunity	_noimmunity	3788	Reference		
	boost2-_alone	516	0.82 (0.63, 1.07)	0.149	
	boost2+_alone	246	1.09 (0.75, 1.56)	0.649	
	full2-_alone	175	0.43 (0.24, 0.71)	0.002	
	full2+_alone	1920	0.64 (0.54, 0.74)	<0.001	
	full2+_inf6-	3	0.00 (NA, 2243344685955.21)	0.970	
	inf6-_alone	8	0.80 (0.04, 4.61)	0.838	
	inf6+_alone	24	1.13 (0.37, 2.86)	0.812	
	inf6+_boost2-	5	0.00 (NA, 313632.44)	0.960	
	inf6+_boost2+	3	0.00 (NA, 1091790144331.05)	0.969	
	inf6+_full2-	2	0.00 (NA, 211411878393342885888.00)	0.975	
	inf6+_full2+	30	0.18 (0.01, 0.86)	0.095	
	part2-_alone	109	0.69 (0.38, 1.17)	0.194	
	AgeGr	_40-64	1591	Reference	
		0-24	447	0.42 (0.29, 0.59)	<0.001
25-39		492	0.46 (0.33, 0.64)	<0.001	
65+		4299	0.82 (0.71, 0.95)	0.010	
Sex	M	3370	Reference		
	Z	3459	0.63 (0.55, 0.72)	<0.001	

0.1 1000e+07e+11e+15e+19